PT-141 works by acting on your central nervous system to increase sexual desire and performance. It is also used to treat erectile dysfunction.
Most of the clinical trials studying the benefits of PT-141 have been focused on answering two main questions: Does it work, and is it safe?
A team of medical researchers conducted a clinical study on the use of PT-141 for male sexual dysfunction. They evaluated the quality of erections using the RigiScan Plus System, which allows scientists to measure the frequency, duration, and rigidity of an erection.
They discovered that participants who were on PT-141 demonstrated significant erectile activity, while participants on placebo did not. In addition, PT-141 was generally safe and well-tolerated.
These scientists concluded, “PT-141 is erectogenic in both experimental animals and humans . . . The data suggests a potential role for PT-141 for the treatment of male erectile dysfunction.”
PT-141 also works differently from other common sexual dysfunction medications, such as Viagra and Cialis. This means that individuals who do not respond well to other sexual dysfunction drugs may achieve a satisfactory response using PT-141. PT-141 can also work synergistically with existing medications to help you develop stronger and longer lasting erections.
PT-141 has been demonstrated to do more than improve erection quality. When surveyed and compared to placebo, men on PT-141 reported greater satisfaction and enjoyment from sex, greater frequency of orgasm/climax, increased desire, and overall confidence in their ability to get and keep an erection.
References
Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. doi:10.1111/j.1749-6632.2003.tb03167.x
Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005;65(4):755-759. doi:10.1016/j.urology.2004.10.060
Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-1071. doi:10.1016/j.juro.2007.10.063
Disclaimer: The contents of this article, including, but not limited to, text, graphics, images, and other information, is for information purposes only and does not constitute medical advice. The information contained herein is not a substitute for and should never be relied upon for professional medical advice. The content is not meant to be complete or exhaustive or to be applicable to any specific individual's medical condition. You should consult a licensed healthcare professional before starting any health protocol and seek the advice of your physician or other medical professional if you have questions or concerns about a medical condition. Always talk to your doctor about the risks and benefits of any treatment. Never disregard or delay seeking professional medical advice or treatment because of something you have read on this site. Maximus does not recommend, endorse, or make any representation about the efficacy, appropriateness, or suitability of any specific test, products, procedures, treatments, services, opinions, healthcare providers or other information contained herein. Maximus is not responsible for, nor will they bear any liability for, the content provided herein or any actions or outcomes resulting from or related to its use.
